Method Of Making A Transgenic Nonhuman Animal Patents (Class 800/21)
-
Patent number: 8552254Abstract: The present invention provides novel methods of maintaining genetic stability of non-human animal inbred strains. In the methods, pedigree-tracked cryopreserved embryos or gametes or pre-gametes derived from a foundation colony are produced and used to re-establish the foundation colony at appropriate intervals.Type: GrantFiled: October 26, 2009Date of Patent: October 8, 2013Assignee: The Jackson LaboratoryInventors: Michael V. Wiles, Robert Taft, Eva M. Eicher, Shannon Byers
-
Publication number: 20130263292Abstract: The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.Type: ApplicationFiled: March 29, 2012Publication date: October 3, 2013Applicant: Kymab LimitedInventors: Qi Liang, Allan Bradley, E-Chiang Lee, Wei Wang, Dominik Spensberger, Hui Liu, Jasper Clube
-
Patent number: 8546643Abstract: The present invention relates to a genetically modified pig as a model for studying atherosclerosis. The modified pig model displays one or more phenotypes associated with atherosclerosis. Disclosed is also a modified pig comprising a mutation in the endogenous ApoE gene or part thereof, LDL gene or part thereof, LDL receptor gene, or transcriptional or translational product or part thereof. The invention further relates to methods for producing the modified pig; and methods for evaluating the effect of a therapeutical treatment of atherosclerosis; methods for screening the efficacy of a pharmaceutical composition; and a method for treatment of a human being suffering from atherosclerosis are disclosed.Type: GrantFiled: March 6, 2008Date of Patent: October 1, 2013Assignee: Aarhus UniversitetInventors: Jacob Fog Bentzon, Charlotte Brandt Sørensen, Peter Michael Kragh, Jacob Giehm Mikkelsen, Erling Falk, Lars Axel Bolund, Thomas Juhl Corydon
-
Publication number: 20130254911Abstract: Mice are provided that comprise a reduction or deletion of ADAM6 activity from an endogenous ADAM6 locus, or that lack an endogenous locus encoding a mouse ADAM6 protein, wherein the mice comprise a sequence encoding an ADAM6 or ortholog or homolog or fragment thereof that is functional in a male mouse. In one embodiment, the sequence is an ectopic ADAM6 sequence or a sequence that confers upon a male mouse the ability to generate offspring by mating. Mice and cells with genetically modified immunoglobulin heavy chain loci that comprise an ectopic nucleotide sequence encoding a mouse ADAM6 or functional fragment or homolog or ortholog thereof are also provided.Type: ApplicationFiled: May 9, 2013Publication date: September 26, 2013Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Lynn Macdonald, Sean Stevens, Andrew J. Murphy
-
Publication number: 20130254907Abstract: This present invention relates to transgenic animals useful to study human diseases. Specifically, the invention relates to transgenic animals expressing at least two human proteins (optionally in replacement of the counterpart proteins in the animal) whereas a first human protein interacts with a second human protein. The transgenic animals can then be used for evaluating drugs or building disease models that are related to the expressed human proteins in the animals. The animals and methods disclosed herein reduce the possibility identifying a false-positive compound—the compound that show an effect in a naturally-occurring, non-transgenic animal but may not necessarily work or be therapeutic in human, since the compound may only interrupt the interaction between two animal proteins not necessarily two related human proteins.Type: ApplicationFiled: November 28, 2011Publication date: September 26, 2013Inventor: James Zhu
-
Publication number: 20130254909Abstract: Synthetic regulation of gene expression is provided. In some embodiments, synthetic regulatory constructs are provided. In some embodiments, a synthetic regulatory construct expresses a heterologous gene in a selected cell type. In some embodiments, methods of expressing a heterologous gene in a selected cell type are provided.Type: ApplicationFiled: March 4, 2013Publication date: September 26, 2013Applicant: Duke UniversityInventors: Matthew S. Marengo, Mariano A. Garcia-Blanco
-
Patent number: 8541033Abstract: The present invention provides an immunodeficient mouse (NOG mouse) suitable for engraftment, differentiation and proliferation of heterologous cells, and a method of producing such a mouse. This mouse is obtained by backcrossing a C.B-17-scid mouse with an NOD/Shi mouse, and further backcrossing an interleukin 2-receptor ?-chain gene-knockout mouse with the thus backcrossed mouse. It is usable for producing a human antibody and establishing a stem cell assay system, a tumor model and a virus-infection model.Type: GrantFiled: November 17, 2009Date of Patent: September 24, 2013Assignee: Central Institute for Experimental AnimalsInventors: Mamoru Ito, Kimio Kobayashi, Tatsutoshi Nakahata, Koichiro Tsuji, Sonoko Habu, Yoshio Koyanagi, Naoki Yamamoto, Kazuo Sugamura, Kiyoshi Ando, Tatsuji Nomura
-
Publication number: 20130247233Abstract: The present invention provides GPCR polypeptides and polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypeptides and polynucleotides are useful, for example, in methods of diagnosis and treatment of diseases and disorders. The invention also provides methods for identifying compounds (e.g., agonists or antagonists) using the GPCR polypeptides and polynucleotides of the invention, and for treating conditions associated with GPCR dysfunction with the GPCR polypeptides, polynucleotides, or identified compounds. The invention also provides diagnostic assays for detecting diseases or disorders associated with inappropriate GPCR activity or levels.Type: ApplicationFiled: March 12, 2013Publication date: September 19, 2013Applicant: OMEROS CORPORATIONInventors: George A. Gaitanaris, John E. Bergmann, Alexander Gragerov, John Hohmann, Fusheng Li, Linda Madisen, Kellie L. McIlwain, Maria N. Pavlova, Demetri Vassilatis, Hongkui Zeng
-
Publication number: 20130247236Abstract: Genetically modified non-human animals are provided that express an immunoglobulin variable domain that comprises at least one histidine, wherein the at least one histidine is encoded by a substitution of a non-histidine codon in the germline of the animal with a hisidine codon, or the insertion of a histidine codon in a germline immunoglobulin nucleic acid sequence. Immunoglobulin genes comprising histidines in one or more CDRs, in an N-terminal region, and or in a loop 4 region are also provided. Immunoglobulin variable domains comprising one or more histidines (e.g., histidine clusters) substituted for non-antigen-binding non-histidine residues. Non-human animals that are progeny of animals comprising modified heavy chain variable loci (V, D, J segments), modified light chain variable loci (V, J segments), and rearranged germline light chain genes (VJ sequences) are also provided. Non-human animals that make immunoglobulin domains that bind antigens in a pH-sensitive manner are provided.Type: ApplicationFiled: March 15, 2013Publication date: September 19, 2013Applicant: Regeneron Pharmaceuticals, Inc.Inventors: John McWhirter, Lynn Macdonald, Joel H. Martin, Andrew J. Murphy
-
Publication number: 20130247234Abstract: A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of pH dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses a single light chain variable domain derived from a single rearranged light chain variable region gene in the germline of the non-human animal, wherein the single rearranged light chain variable region gene comprises a substitution of at least one non-histidine encoding codon with a histidine encoding codon. Methods of making non-human animals that express antibodies comprising a histidine-containing universal light chain are provided.Type: ApplicationFiled: March 15, 2013Publication date: September 19, 2013Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: John MCWHIRTER, Lynn MACDONALD, Andrew J. MURPHY
-
Publication number: 20130243759Abstract: The present invention relates inter alia to fertile non-human vertebrates such as mice and rats useful for producing antibodies bearing human variable regions, in which endogenous antibody chain expression has been inactivated.Type: ApplicationFiled: March 15, 2013Publication date: September 19, 2013Applicant: KYMAB LTD.Inventors: Glenn A. Friedrich, E-Chiang Lee
-
Publication number: 20130247235Abstract: Genetically modified non-human animals are provided that comprise an immunoglobulin heavy chain locus comprising an unrearranged human heavy chain variable region nucleotide sequence comprising an addition of at least one histidine codon or a substitution of at least one endogenous non-histidine codon with a histidine codon. Compositions and methods for making the genetically modified non-human animals as described herein are provided. Non-human animals capable of expressing an antigen-binding protein characterized by pH-dependent antigen binding, enhanced recyclability and/or enhanced serum half-life are also provided.Type: ApplicationFiled: March 15, 2013Publication date: September 19, 2013Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: John MCWHIRTER, Lynn MACDONALD, Andrew J. MURPHY
-
Publication number: 20130227720Abstract: Rationally-designed LAGLIDADG meganucleases and methods of making such meganucleases are provided. In addition, methods are provided for using the meganucleases to generate recombinant cells and organisms having a desired DNA sequence inserted into a limited number of loci within the genome, as well as methods of gene therapy, for treatment of pathogenic infections, and for in vitro applications in diagnostics and research.Type: ApplicationFiled: April 11, 2013Publication date: August 29, 2013Applicant: DUKE UNIVERSITYInventor: Duke University
-
Publication number: 20130219535Abstract: The present invention comprises non-human vertebrate cells and non-human mammals having a genome comprising an introduced partially human immunoglobulin region, said introduced region comprising human VH coding sequences and non-coding VH sequences based on the endogenous genome of the non-human mammal.Type: ApplicationFiled: July 26, 2011Publication date: August 22, 2013Applicant: TRIANNI, INCInventors: Matthias Wabl, Nigel Killeen
-
Publication number: 20130212718Abstract: Transgenic silkworms comprising at least one nucleic acid encoding a chimeric silk polypeptide comprising one or more spider silk elasticity and strength motifs are disclosed. Expression cassettes comprising nucleic acids encoding a variety of chimeric spider silk polypeptides (Spider 2, Spider 4, Spider 6, Spider 8) are also disclosed. A piggyBac vector system is used to incorporate nucleic acids encoding chimeric spider silk polypeptides into the mutant silkworms to generate stable transgenic silkworms. Chimeric silk fibers having improved tensile strength and elasticity characteristics compared to native silkworm silk fibers are also provided. The transgenic silkworms greatly facilitate the commercial production of chimeric silk fibers suitable for use in a wide variety of medical and industrial applications.Type: ApplicationFiled: March 28, 2013Publication date: August 15, 2013Inventors: Malcolm James FRASER, Randy LEWIS, Don JARVIS, Kimberly THOMPSON, Joseph HULL, Yun-Gen MIAO, Florence TEULE, Bonghee SOHN, Youngsoo KIM
-
Publication number: 20130212722Abstract: Disclosed are materials and methods for creating customizable traits in animals. In the demonstration of the principle of the subject invention, a keratin-14 specific promoter is used with, red fluorescent protein in the loxp cassette, dominant black (?G23) beta defensin 103 in the pigment cassette, and an SV40 (with intron) polyadenylation sequence. When Cre recombinase (or HTNCre) is applied to the animal's skin in a carrier base (e.g., lipid bilayers), fur is permanently genetically modified to turn black in the shape in which it was applied.Type: ApplicationFiled: February 15, 2013Publication date: August 15, 2013Applicant: MICE WITH HORNS, LLCInventor: Mice With Horns, LLC
-
Publication number: 20130212725Abstract: The present invention relates to a method of modifying a target sequence in the genome of a eukaryotic cell, the method comprising the step: (a) introducing into the cell a fusion protein comprising a DNA-binding domain of a Tal effector protein and a non-specific cleavage domain of a restriction nuclease or a nucleic acid molecule encoding the fusion protein in expressible form, wherein the fusion protein specifically binds within the target sequence and introduces a double strand break within the target sequence. The present invention further relates to the method of the invention, wherein the modification of the target sequence is by homologous recombination with a donor nucleic acid sequence further comprising the step: (b) introducing a nucleic acid molecule into the cell, wherein the nucleic acid molecule comprises the donor nucleic acid sequence and regions homologous to the target sequence.Type: ApplicationFiled: June 7, 2011Publication date: August 15, 2013Applicant: HELMHOLTZ ZENTRUM MUNCHEN DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UNDInventors: Ralf Kühn, Wolfgang Wurst, Melanie Meyer
-
Publication number: 20130212717Abstract: Pentameric CRP is produced at a high efficiency by transferring DNA, which encodes monomeric CRP, into a silkworm to thereby construct a transgenic silkworm and then collecting and purifying pentameric CRP that is produced by the transgenic silkworm constructed above.Type: ApplicationFiled: May 30, 2011Publication date: August 15, 2013Applicants: NATIONAL INSTITUE OF AGROBIOLOGICAL SCIENCES, NITTO BOSEKI CO., LTD.Inventors: Iwao Kiyokawa, Yuji Arimatsu, Toshihide Miura, Ryo Kojima, Hideki Sezutsu, Keiro Uchino, Isao Kobayashi, Toshiki Tamura
-
Publication number: 20130212719Abstract: Non-human animals, tissues, cells, and genetic material are provided that comprise a modification of an endogenous non-human heavy chain immunoglobulin sequence and that comprise an ADAM6 activity functional in a rodent (e.g., a mouse), wherein the non-human animals rearrange human immunoglobulin light chain gene segments in the context of heavy chain constant regions and express immunoglobulin-like molecules comprising human immunoglobulin light chain variable domains fused to heavy chain constant domains that are cognate with human immunoglobulin light chain variable domains fused to light chain constant domains.Type: ApplicationFiled: February 1, 2013Publication date: August 15, 2013Applicant: Regeneron Pharmaceuticals, Inc.Inventor: Regeneron Pharmaceuticals, Inc.
-
Patent number: 8502018Abstract: A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.Type: GrantFiled: June 20, 2011Date of Patent: August 6, 2013Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Andrew J. Murphy, George D. Yancopoulos
-
Patent number: 8502015Abstract: A method induces cancer, such as ovarian cancer, in primates for testing of therapeutic treatments and preclinical research and development. A nanoparticle delivers plasmid DNA encoding oncogenes and siRNAs for tumor suppressor genes. For example, a biocompatible polymer, chitosan, is complexed with three plasmids including one that carries the cDNA encoding RAS oncogene and two plasmids encoding siRNAs for two tumor supressor genes p53 and Rb. Laproscopic delivery of these nanoparticles to the ovaries of non-human primates causes ovarian carcinoma, which is detected one month after delivery of the nanoparticles.Type: GrantFiled: July 6, 2010Date of Patent: August 6, 2013Inventor: Weidong Xu
-
Publication number: 20130198878Abstract: Disclosed herein are homozygously modified organisms and methods of making and using these organisms.Type: ApplicationFiled: March 14, 2013Publication date: August 1, 2013Applicant: C/O SANGAMO BIOSCIENCES, INC.Inventor: C/O SANGAMO BIOSCIENCES, INC.
-
Publication number: 20130174284Abstract: The present invention relates to a recombinant vector and a transgenic mouse for expressing human ferritin in a tissue non-specific manner, and more particularly, to a vector prepared by operably linking a human ferritin gene to a promoter including a cytomegalovirus (CMV) early enhancer element and a ?-actin promoter, and a transgenic mouse expressing human ferritin in a tissue non-specific manner, which is transformed with the vector. Further, the present invention relates to a method for preparing a transgenic mouse, and a method for monitoring cell or tissue therapy using the transgenic mouse.Type: ApplicationFiled: July 7, 2011Publication date: July 4, 2013Applicant: SNU R&DB FOUNDATIONInventors: Woo Kyung Moon, Hoe Suk Kim
-
Publication number: 20130160152Abstract: The present invention provides PiggyBac transposase proteins, nucleic acids encoding the same, compositions comprising the same, kits comprising the same, non-human transgenic animals comprising the same, and methods of using the same.Type: ApplicationFiled: February 22, 2013Publication date: June 20, 2013Applicant: Transposagen Biopharmaceuticals, Inc.Inventors: Eric Ostertag, Blair Madison
-
Publication number: 20130150465Abstract: The present invention relates to a genetically modified pig as a model for studying breast cancer, mitochondria related protein folding disorders and/or epidermolysis bullosa simplex. The modified pig model displays one or more phenotypes associated with any of said disorders. Disclosed is also a modified pig comprising a modified endogeneous BRCA1 and/or BRCA2 gene, and/or a modified ornithine transcarbamylase gene, and/or a modified Keratin 14 gene and/or a transcriptional or translational product or part thereof. The invention further relates to methods for producing the modified pig; and methods for evaluating the effect of a therapeutical treatment of breast cancer, mitochondria related protein folding disorders and/or epidermolysis bullosa simplex; methods for screening the efficacy of a pharmaceutical composition; and a method for treatment of a human being suffering from breast cancer, mitochondria related protein folding disorders and/or epidermolysis bullosa simplex are disclosed.Type: ApplicationFiled: August 22, 2012Publication date: June 13, 2013Applicant: Aarhus UniversitetInventors: Peter Michael Kragh, Lars Axel Bolund, Charlotte Brandt Sørensen, Thomas Juhl Corydon, Niels Gregersen, Peter Bross
-
Publication number: 20130145487Abstract: The invention relates to meganuclease variants which cleave a DNA target sequence from the human dystrophin gene (DMD), to vectors encoding such variants, to a cell, an animal or a plant modified by such vectors and to the use of these meganuclease variants and products derived therefrom for genome therapy, ex vivo (gene cell therapy) and genome engineering including therapeutic applications and cell line engineering. The invention also relates to the use of meganuclease variants for inserting therapeutic transgenes other than DMD at the dystrophin gene locus, using this locus as a safe harbor locus. The invention also relates to the use of meganuclease variants for using the dystrophin gene locus as a landing pad to insert and express genes of interest.Type: ApplicationFiled: May 12, 2011Publication date: June 6, 2013Applicant: CELLECTISInventor: Frédéric Cedrone
-
Publication number: 20130145488Abstract: The invention provides gold-plated mesoporous silicate bodies comprising pores and at least one agent and methods of using those bodies.Type: ApplicationFiled: December 6, 2012Publication date: June 6, 2013Applicant: Iowa State University Research Foundation, Inc.Inventors: Kan Wang, Brian G. Trewyn, Susana Martin-Ortigosa, Justin Valenstein
-
Publication number: 20130133093Abstract: The present invention relates to the method and use of reef coral fluorescent proteins in making transgenic red, green and yellow fluorescent zebrafish. Preferably, such fluorescent zebrafish are fertile and used to establish a population of transgenic zebrafish and to provide to the ornamental fish industry for the purpose of marketing. Thus, new varieties of ornamental fish of different fluorescence colors from a novel source are developed.Type: ApplicationFiled: October 29, 2012Publication date: May 23, 2013Applicant: YORKTOWN TECHNOLOGIES, L.P.Inventor: YORKTOWN TECHNOLOGIES, L.P.
-
Publication number: 20130133092Abstract: The present invention relates to a method of sequence specific recombination of DNA in eukaryotic cells utilizing att sequences from the bacteriophage lambda. A particular embodiment of the invention relates to a method further comprising performing the sequence specific recombination of DNA with an Int and a Xis factor. The present invention further relates to vectors containing each of these sequences and their use as medicaments.Type: ApplicationFiled: November 1, 2012Publication date: May 23, 2013Inventor: Dr. Peter Droge
-
Patent number: 8440878Abstract: The present invention relates to a nucleic acid molecule encoding an insulin-like factor of the androgenic gland of the freshwater prawn Macrobrachium rosenbergii (M. rosenbergii). The present invention further relates to methods of silencing the expression of the insulin-like factor gene in decapod crustaceans order, particularly in M. rosenbergii, useful for producing male monosex populations.Type: GrantFiled: October 19, 2011Date of Patent: May 14, 2013Assignee: Ben-Gurion University of the Negev Research and Development AuthorityInventors: Amir Sagi, Tomer Ventura
-
Publication number: 20130117873Abstract: Mice that comprise a replacement of endogenous mouse IL-6 and/or IL-6 receptor genes are described, and methods for making and using the mice. Mice comprising a replacement at an endogenous IL-6R? locus of mouse ectodomain-encoding sequence with human ectodomain-encoding sequence is provided. Mice comprising a human IL-6 gene under control of mouse IL-6 regulatory elements is also provided, including mice that have a replacement of mouse IL-6-encoding sequence with human IL-6-encoding sequence at an endogenous mouse IL-6 locus.Type: ApplicationFiled: October 29, 2012Publication date: May 9, 2013Applicant: Regeneron Pharmaceuticals, Inc.Inventor: Regeneron Pharmaceuticals, Inc.
-
Publication number: 20130111617Abstract: The invention provides genetically modified non-human animals that express chimeric human/non-human MHC I polypeptide and/or human or humanized ?2 microglobulin polypeptide, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.Type: ApplicationFiled: October 26, 2012Publication date: May 2, 2013Applicant: REGENERON PHARMACEUTICALS, INC.Inventor: REGENERON PHARMACEUTICALS, INC.
-
Publication number: 20130111616Abstract: The invention provides genetically modified non-human animals that express a humanized MHC II protein (humanized MHC II ? and ? polypeptides), as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.Type: ApplicationFiled: October 26, 2012Publication date: May 2, 2013Applicant: REGENERON PHARMACEUTICALS, INC.Inventor: REGENERON PHARMACEUTICALS, INC.
-
Publication number: 20130104253Abstract: Methods for de-differentiating or altering the life-span of desired “recipient” cells, e.g., human somatic cells, by the introduction of cytoplasm from a more primitive, less differentiated cell type, e.g., oocyte or blastomere are provided. These methods can be used to produce embryonic stem cells and to increase the efficiency of gene therapy by allowing for desired cells to be subjected to multiple genetic modifications without becoming senescent. Such cytoplasm may be fractionated and/or subjected to subtractive hybridization and the active materials (sufficient for de-differentiation) identified and produced by recombinant methods.Type: ApplicationFiled: September 14, 2012Publication date: April 25, 2013Inventor: Karen B. CHAPMAN
-
Patent number: 8426674Abstract: Silkworms which have (i) a DNA encoding a transcriptional regulator operably linked downstream of a promoter of a DNA encoding a protein specifically expressed in the silk gland and (ii) a DNA encoding TRACP5 operably linked downstream of a target promoter of the transcriptional regulator were produced. The result showed that active TRACP5b was produced from the silkworms. This means that TRACP5 produced from the silk gland of the silkworms undergoes processing in the silk gland that is similar to the processing taking place at bone resorption sites.Type: GrantFiled: December 28, 2007Date of Patent: April 23, 2013Assignees: Nitto Boseki Co., Ltd., National Institute of Agrobiological SciencesInventors: Iwao Kiyokawa, Tatsuya Ohashi, Toshihide Miura, Katsuhiro Katayama, Toshiki Tamura, Isao Kobayashi, Hideki Sezutsu
-
Publication number: 20130061342Abstract: Markers useful for the identification, characterization and, optionally, the enrichment or isolation of tumorigenic cells or cell subpopulations are disclosed.Type: ApplicationFiled: February 8, 2012Publication date: March 7, 2013Inventors: Scott J. Dylla, Marianne Santaguida, Wade C. Anderson, Bob Y. Liu, Samuel A. Williams
-
Publication number: 20130061343Abstract: Disclosed is a FAST (Flexible Accelerated STOP TetO-knockin) system, an efficient method for manipulating gene expression in vivo to rapidly screen animal models of disease. This invention further discloses a single gene targeting event yielding 2 distinct knockin mice—STOP-tetO and tetO knockin—which permit generation of multiple strains with variable expression patterns: 1) knockout, 2) Cre-mediated rescue; 3) tTA-mediated misexpression; 4) tTA-mediated overexpression; and 5) tTS-mediated conditional knockout/knockdown. Using the FAST system, multiple gain- and loss-of-function strains can therefore be generated on a timescale not previously achievable. These strains can then be screened for clinically-relevant abnormalities. The flexibility and broad applicability of the FAST system is demonstrated by targeting several genes encoding proteins implicated in neuropsychiatric disorders: Mlc1, Neuroligin 3, the serotonin 1A receptor, and the serotonin 1B receptor.Type: ApplicationFiled: February 8, 2011Publication date: March 7, 2013Inventors: Rene Hen, Kenji Tanaka
-
Publication number: 20130053628Abstract: A method for cultivating a transgenic animal with an increased expression amount of porcine growth hormone is provided. Additionally, a method for cultivating a transgenic embryo, which introduces a recombinant expression vector of 1) TRE-GH or 2) TET-ON into a target embryo to obtain a transgenic embryo with a higher expression amount of porcine growth hormone than a target embryo without introduction is provided. A transgenic animal can be obtained by transplanting the embryo into an animal. The experiments demonstrate that growth hormone (GH) is sharply increased in blood of transgenic pigs after adding DOX.Type: ApplicationFiled: June 24, 2010Publication date: February 28, 2013Applicant: Institute of Animal Science, Chinese Academy of Agricultural SciencesInventors: Kui Li, Huiming Ju, Xinmin Zheng, Lijing Bai, Wentao Cui, Zhonglin Tang, Yulian Mu, Shulin Yang
-
Patent number: 8383880Abstract: A method of inducing male and/or female infertility in a genetically modified (GM) fish is disclosed. Also disclosed is a method of generating an infertile GM fish with a phenotype and/or genotype of interest. The method involves generation of a GM fish whose genome comprises a foreign transgene operably linked to a fish gonad-specific promoter selected from the group consisting of an ovary-specific promoter and a testis-specific promoter. The transgene comprises a suicide gene selected from the group consisting of a reductase and a photosensitizer, in which the reductase is operably linked to a reporter gene. Infertility of the GM fish is induced if the GM fish expressing the reductase is treated with an effective amount of a reductase-activated cytotoxic prodrug or if the GM fish expressing the photosensitizer is treated with light irradiation.Type: GrantFiled: February 12, 2010Date of Patent: February 26, 2013Assignees: Academia Sinica, National Taiwan Ocean UniversityInventors: Jen-Leih Wu, Shao-Yang Hu, Guor Mour Her
-
Publication number: 20130047273Abstract: A genetically altered animal specimen is provided by a process comprising: identifying a gene that is desired to be altered, disrupting the gene in a gene carrier to thereby create a new DNA fragment; inserting the new DNA fragment into an embryonic cell, injecting the embryonic cell which exhibits the desired genetic alteration into an embryo, inserting the embryo into a uterus of a carrier whereby the carrier's offspring shall exhibit the desired genetic alteration, and the offspring is the genetically altered animal specimen, in this case the neurocalcin ? gene knockout mouse model.Type: ApplicationFiled: August 16, 2011Publication date: February 21, 2013Inventors: Rameshwar K. Sharma, Teresa Duda
-
Publication number: 20130042331Abstract: The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.Type: ApplicationFiled: March 9, 2012Publication date: February 14, 2013Applicant: Kymab LimitedInventors: Allan Bradley, E-Chiang Lee, Qi Liang, Wei Wang, Anais Legent, Ian Kirby
-
Patent number: 8373018Abstract: A process for generating transgenic animals using recombinant lentiviruses. The process comprises injecting recombinant lentiviruses into the interstituim of the testis of a male to produce mature spermatozoa within a few days. The male with transgene expressing lentivirus is mated with a female, forming a progeny carrying the transgene.Type: GrantFiled: January 11, 2011Date of Patent: February 12, 2013Assignees: Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Department of BiotechnologyInventors: Sorab N. Dalal, Lalit Sehgal, Nileema Khapare, Rahul Thorat
-
Patent number: 8367888Abstract: The present invention provides in a first aspect a mouse in which the ? (lambda) light chain locus has been functionally silenced. In one embodiment, the mouse ? light chain locus was functional silenced by deletion of gene segments coding for the ? light chain locus. In a further aspect, a mouse containing functionally silenced ? and ? (kappa) L chain loci was produced. The invention is useful for the production of antibodies, for example heterologous antibodies, including heavy chain only antibodies.Type: GrantFiled: June 1, 2009Date of Patent: February 5, 2013Assignee: Crescendo Biologics LimitedInventors: Marianne Brüggemann, Xiangang Zou
-
Publication number: 20130024959Abstract: The present invention relates to a method of producing a cell comprising a conditionally active transgene in its genome, the method comprising (a) introducing into the cell a targeting vector, wherein the targeting vector comprises (i) a 5? recombinase recognition site specifically recognised by a first recombinase, wherein the first recombinase is endogenously present in the cell or wherein the first recombinase or a nucleic acid molecule encoding said first recombinase in expressible form is introduced into the cell; followed by (ii) a 5? recombinase recognition site specifically recognised by a second recombinase, wherein the second recombinase is not endogenously present or is not active in the cell; followed by (iii) a selection cassette comprising a positively selectable marker gene; followed by (iv) a 3? recombinase recognition site specifically recognised by a third recombinase, wherein the third recombinase is not endogenously present or is not active in the cell; followed by (v) the transgene; folloType: ApplicationFiled: November 24, 2010Publication date: January 24, 2013Applicants: UNIVERSITY OF FRANKFURT-MEDICAL SCHOOL, HELMHOLTZ ZENTRUM MÜNCHEN-DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH)Inventors: Laura Schebelle, Frank Schnütgen, Thomas Floss
-
Patent number: 8354568Abstract: The invention provides a novel approach to increase immunoglobulin expression in non-human transgenic animals. For instance, the invention provides a method to increase humanized immunoglobulin production in animals genetically engineered to express one or several human or humanized immunoglobulin transloci. This can be done by overexpressing the apoptosis inhibitor, i.e. a rabbit bcl-2, whose expression is driven by a B-cell specific promoter specifically in the B-cell of the animal, thereby enhancing the survival of B-cells. This invention further relates to a method for selectively enhancing the survival of exogenous B-cells, that is B-cells expressing any immunoglobulin transgene locus, over the survival of endogenous B-cells that do not express the transgene locus. Selectivity is achieved by expressing the apoptosis-inhibitor only within exogenous B-cells, that is, by coupling exogenous immunoglobulin expression with apoptosis inhibitor expression.Type: GrantFiled: March 17, 2011Date of Patent: January 15, 2013Assignee: Therapeutic Human Polyclonals, Inc.Inventors: Roland Buelow, Josef Platzer
-
Publication number: 20130007904Abstract: Genetic material is derived from animals post-mortem, and used in nuclear transfer processes to produce cloned embryos and live cloned animals having genetic make-ups identical to the post mortem animals. The method has particular applicability to the management and breeding of livestock, to the production of animals having desired genetic traits, and to the integration of those genetic traits into selective breeding operations.Type: ApplicationFiled: May 29, 2012Publication date: January 3, 2013Applicants: Viagen, Inc., University of Georgia Research Foundation, Inc.Inventors: Steven L. Stice, John Gibbons, Donald Respess
-
Publication number: 20120322108Abstract: Mice are provided that comprise a reduction or deletion of ADAM6 activity from an endogenous ADAM6 locus, or that lack an endogenous locus encoding a mouse ADAM6 protein, wherein the mice comprise a sequence encoding an ADAM6 or ortholog or homolog or fragment thereof that is functional in a male mouse. In one embodiment, the sequence is an ectopic ADAM6 sequence or a sequence that confers upon a male mouse the ability to generate offspring by mating. Mice and cells with genetically modified immunoglobulin heavy chain loci that comprise an ectopic nucleotide sequence encoding a mouse ADAM6 or functional fragment or homolog or ortholog thereof are also provided.Type: ApplicationFiled: February 24, 2012Publication date: December 20, 2012Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Lynn Macdonald, Sean Stevens, Andrew J. Murphy
-
Publication number: 20120317666Abstract: The present invention relates to transgenic blue ornamental fish, as well as methods of making such fish by in vitro fertilization techniques. Also disclosed are methods of establishing a population of such transgenic fish and methods of providing them to the ornamental fish industry for the purpose of marketing.Type: ApplicationFiled: July 30, 2012Publication date: December 13, 2012Inventors: Alan Blake, Richard Crockett, Aidas Nasevicius
-
Publication number: 20120317665Abstract: The present invention relates to the method and use of fluorescent proteins in making purple transgenic fluorescent fish. Also disclosed are methods of establishing a population of such transgenic fish and methods of providing them to the ornamental fish industry for the purpose of marketing. Thus, new varieties of ornamental fish of different fluorescence colors from a novel source are developed.Type: ApplicationFiled: July 30, 2012Publication date: December 13, 2012Inventors: Alan Blake, Richard Crockett, Aidas Nasevicius
-
Patent number: 8329980Abstract: The invention relates to the production of proteins and other substances of interest in saliva of transgenic animals, particularly in mammals that produce large quantities of saliva, particularly monogastric ruminants, and ovine, caprine and bovine mammals. Preferred embodiments of the invention relate in particular to the production of foreign and modified proteins in the transgenic saliva of these animals, including particularly human fibrinogen, human prothrombin and human thrombin, among others. The invention relates as well to methods, devices, genetic constructs and to transgenic constructs for making the proteins and other substances of interest, to novel saliva and saliva-derived compositions, novel products produced from the saliva, and to uses of the saliva, saliva-derived compositions and novel products.Type: GrantFiled: July 12, 2010Date of Patent: December 11, 2012Inventor: Jeffrey P. Erickson